Time in chemo-immunotherapy models: an absolute or a relative variable? Lessons from the levamisole experience.
An analysis is presented of the findings from the available studies in several cancer models, where 2.5-20 mg/kg levamisole was given in combination with different types of cytostatic drugs. It appears that in chemo-immunotherapy experiments it may be preferable to measure time variables (increase in life span, timing of chemotherapy and of immunotherapy) as a per cent of the median survival time of the untreated controls instead of using time as an absolute measure (in days). As regards the study of levamisole in chemo-imnmunotherapy models, the increase in life span by the cytostatic alone seems to be the most important variable studied here. An "optimal" protocol for the evaluation of levamisole is proposed based upon all the findings of this analysis.
D000818:Animals; D007167:Immunotherapy; D007978:Levamisole / Q000627:therapeutic use*; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000628:therapy*; D012107:Research Design; D013997:Time Factors
D007978:Levamisole